Efficacy of the fully human anti-TNF antibody D2E7 in rheumatoid arthritis.

被引：0
|
作者：
van de Putte, BA
Rau, R
Breedveld, FC
Kalden, JR
Malaise, MG
Schattenkirchner, M
Emery, P
Burmester, GR
Zeidler, H
Moutsopoulos, HH
Compagnone, D
Kempeni, J
Kupper, H
机构：
来源：
ARTHRITIS AND RHEUMATISM | 1999年 / 42卷 / 09期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1977
引用
收藏
页码：S400 / S400
页数：1
相关论文
共 50 条
  • [31] Arrest in bone loss during Anti-TNF treatment in patients with rheumatoid arthritis.
    Boyesen, Pernille
    Haavardshom, Espen
    Haugeberg, Glenn
    Kvien, Tore K.
    ARTHRITIS AND RHEUMATISM, 2006, 54 (09): : S200 - S201
  • [32] TNF alpha promoter polymorphism influences outcome of anti-TNF alpha therapy in rheumatoid arthritis.
    Mugnier, B
    Balandraud, N
    Darque, A
    Mercier, P
    Roudier, C
    Roudier, J
    Reviron, D
    GENES AND IMMUNITY, 2004, 5 : S34 - S34
  • [33] Pharmacokinetics and pharmacodynamics of a human anti-TNF-alpha monoclonal antibody in patients with rheumatoid arthritis.
    Jang, H
    Marini, JC
    Pendley, C
    Jiao, Q
    Marciniak, SJ
    Cohen, S
    Fleischmann, R
    Everitt, DE
    Davis, HM
    Graham, MA
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2004, 75 (02) : P53 - P53
  • [34] Low baseline serum cortisol predicts marked clinical improvement 7 days after initiation of Anti-TNF antibody therapy in rheumatoid arthritis.
    Straub, Rainer H.
    Härle, Peter
    Pongratz, Georg
    Fleck, Martin
    Cutolo, Maurizio
    Atzeni, Fabiola
    Antoni, Christian
    Kalden, Joachim
    Lorenz, Hanns-Martin
    Satzi-Puttini, Piercarlo
    ARTHRITIS AND RHEUMATISM, 2006, 54 (09): : S411 - S411
  • [35] Assessment of anti-TNF efficacy in rheumatoid arthritis -: Is three months sufficient?
    Pocock, J. M.
    Oestoer, A. J.
    RHEUMATOLOGY, 2008, 47 : II42 - II42
  • [36] In vitro and in vivo comparison of adalimumab (D2E7), a fully human Anti-TNF-α monoclonal antibody, expressed in transfected CHO cells versus transgenic goats.
    Kaymakçalan, Z
    Sakorafas, P
    Xiong, L
    Beam, C
    Kalghatgi, L
    Stanley, K
    Avgerinos, G
    Salfeld, J
    CLINICAL IMMUNOLOGY, 2002, 103 (03) : S103 - S103
  • [37] Dose escalation of the anti-TNF alpha agents in patients with rheumatoid arthritis. A systematic review
    Ariza-Ariza, R.
    Hernandez-Cruz, B.
    Mendoza, D.
    Rodriguez-Arboleya, L.
    Navarro, M.
    Toyos, J.
    Navarro-Sarabia, F.
    ANNALS OF THE RHEUMATIC DISEASES, 2006, 65 : 174 - 174
  • [38] Prolactin Is Increased in Responders to Anti-TNFα Treatment and the Role of the Prolactin Receptor in Rheumatoid Arthritis.
    Tang, Man Wai
    Gerlag, Danielle Marie
    Codullo, Veronica
    Vieira-Sousa, Elsa
    Reuwer, Anne Q.
    Twickler, Marcel T.
    Landewe, Robert B. M.
    Tak, Paul Peter
    ARTHRITIS AND RHEUMATISM, 2012, 64 (10): : S464 - S464
  • [39] Risk of serious infections and malignancies with anti-TNF antibody therapy in rheumatoid arthritis
    Costenbader, Karen H.
    Glass, Roberta
    Cui, Jing
    Shadick, Nancy
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2006, 296 (18): : 2201 - 2201
  • [40] Do anti-TNF agents have equal efficacy in patients with rheumatoid arthritis?
    Sergio Schwartzman
    Roy Fleischmann
    G James Morgan
    Arthritis Research & Therapy, 6
12345